Hana Pharm Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.34%

Hana Pharm Co Ltd (293480) has an Asset Resilience Ratio of 1.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩5.43 Billion

≈ $3.68 Million USD Cash + Short-term Investments

Total Assets

₩405.15 Billion

≈ $274.57 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Hana Pharm Co Ltd's Asset Resilience Ratio has changed over time. Check Hana Pharm Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Hana Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Hana Pharm Co Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩5.43 Billion	1.34%
Total Liquid Assets	₩5.43 Billion	1.34%

Asset Resilience Insights

Limited Liquidity: Hana Pharm Co Ltd maintains only 1.34% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hana Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hana Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	Drug Manufacturers - Specialty & Generic	20.44%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	48.48%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	11.69%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Tibet Rhodiola Pharmaceutical Holding Co SHG:600211	Drug Manufacturers - Specialty & Generic	15.57%
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	Drug Manufacturers - Specialty & Generic	24.59%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	18.70%

Annual Asset Resilience Ratio for Hana Pharm Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Hana Pharm Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.95%	₩3.64 Billion ≈ $2.47 Million	₩382.01 Billion ≈ $258.88 Million	-0.41pp
2023-12-31	1.36%	₩4.73 Billion ≈ $3.21 Million	₩348.39 Billion ≈ $236.10 Million	-0.10pp
2022-12-31	1.46%	₩5.03 Billion ≈ $3.41 Million	₩345.96 Billion ≈ $234.46 Million	-15.10pp
2021-12-31	16.56%	₩50.25 Billion ≈ $34.05 Million	₩303.50 Billion ≈ $205.68 Million	-2.54pp
2020-12-31	19.10%	₩52.83 Billion ≈ $35.80 Million	₩276.58 Billion ≈ $187.43 Million	-9.19pp
2019-12-31	28.29%	₩74.42 Billion ≈ $50.44 Million	₩263.03 Billion ≈ $178.25 Million	-8.56pp
2018-12-31	36.85%	₩89.32 Billion ≈ $60.53 Million	₩242.38 Billion ≈ $164.26 Million	+34.34pp
2017-12-31	2.51%	₩3.55 Billion ≈ $2.41 Million	₩141.55 Billion ≈ $95.93 Million	+0.96pp
2016-12-31	1.54%	₩1.77 Billion ≈ $1.20 Million	₩114.59 Billion ≈ $77.66 Million	--

pp = percentage points

About Hana Pharm Co Ltd

KO:293480 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$101.53 Million

₩149.81 Billion KRW

Market Cap Rank

#19063 Global

#894 in Korea

Share Price

₩8660.00

Change (1 day)

+1.88%

52-Week Range

₩8250.00 - ₩12290.00

All Time High

₩26028.86